{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:51:20Z","timestamp":1787507480822,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cytomegalovirus causes morbidity and mortality, especially in immunocompromised patients, and is treated with (val)ganciclovir. Therapeutic drug monitoring of ganciclovir is often performed; however, clinically established target trough levels corresponding to efficacy are lacking. In 2021, our clinic increased the target trough level for ganciclovir from 1 to 2 mg\/L to 2\u20134 mg\/L. This study aims to compare both target trough levels in efficacy, toxicity, and occurrence of resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study was performed in adult solid organ recipients treated for cytomegalovirus infection with (val)ganciclovir. Clinical efficacy was defined as the absence of treatment failure, defined as &gt; 1 log\n                      <jats:sub>10<\/jats:sub>\n                      increase in viral load within 2 weeks of treatment initiation, therapy switch to foscarnet, and\/or request for resistance analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 46 patients were involved in the study, with 200 ganciclovir trough levels obtained. The composite endpoint was recorded in 23 (69.7%) and 10 (76.9%) patients in the 1\u20132 mg\/L and the 2\u20134 mg\/L group, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.18). No association was found between ganciclovir trough levels and the composite endpoint (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 1.0). However, a correlation was found between ganciclovir trough levels and the occurrence of lymphopenia (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our study could not establish a difference in clinical efficacy or toxicity between target trough levels of 1\u20132 mg\/L or 2\u20134 mg\/L because of the lack of clinical differences between the compared groups. However, a correlation was found between ganciclovir trough levels and lymphopenia, which warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001054","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T18:28:25Z","timestamp":1675362505000},"page":"533-538","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Therapeutic Drug Monitoring of Ganciclovir in Cytomegalovirus-Infected Patients With Solid Organ Transplants and Its Correlation to Efficacy and Toxicity"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8674-1448","authenticated-orcid":false,"given":"Lena C.","family":"van der Wekken-Pas","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, University Medical Centre, Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Tott\u00e9","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology. University Medical Centre, Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans V.","family":"Lunel","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology. University Medical Centre, Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"van Zuilen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Centre, Utrecht, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"van Luin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Centre, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007691-200402000-00014","article-title":"Ganciclovir in solid organ transplant recipients","volume":"26","author":"Scott","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/jac\/dkab195","article-title":"Ganciclovir therapeutic drug monitoring in transplant recipients","volume":"76","author":"M\u00e4rtson","year":"2021","journal-title":"J Antimicrob Chemother."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients\u2014guidelines of the American society of transplantation infectious diseases community of practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transpl."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJM199609053351007","article-title":"Ganciclovir","volume":"335","author":"Crumpacker","year":"1996","journal-title":"N Engl J Med."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/FTD.0000000000000598","article-title":"Ganciclovir therapeutic drug monitoring: a case series","volume":"41","author":"M\u00e4rtson","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/17425255.2015.988139","article-title":"Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection","volume":"11","author":"Stockmann","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/antibiotics10010077","article-title":"Valganciclovir\u2014ganciclovir use and systematic therapeutic drug monitoring. An invitation to antiviral stewardship","volume":"10","author":"Galar","year":"2021","journal-title":"Antibiot."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/infdis\/174.1.188","article-title":"Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS","volume":"174","author":"Piketty","year":"1996","journal-title":"J Infect Dis."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1469-0691.2000.00014.x","article-title":"Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis","volume":"6","author":"Piketty","year":"2000","journal-title":"Clin Microbiol Infect."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"e01855","DOI":"10.1128\/AAC.01855-18","article-title":"Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety","volume":"63","author":"Ritchie","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1128\/AAC.02130-15","article-title":"Contribution of population pharmacokinetics to dose optimization of ganciclovir-valganciclovir in solid-organ transplant patients","volume":"60","author":"Padull\u00e9s","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jac\/dkv342","article-title":"Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?","volume":"71","author":"Billat","year":"2016","journal-title":"J Antimicrob Chemother."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1128\/AAC.00836-08","article-title":"Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir","volume":"53","author":"Perrottet","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"S849","DOI":"10.1093\/clinids\/12.Supplement_7.S849","article-title":"Management of cytomegalovirus disease with antiviral drugs","volume":"12","author":"Balfour","year":"1990","journal-title":"Clin Infect Dis."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.02953-14","article-title":"Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-Specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients","volume":"58","author":"Gim\u00e9nez","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1128\/AAC.00375-13","article-title":"Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir","volume":"57","author":"Trevillyan","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2334-10-2","article-title":"Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+\/R- transplant recipients","volume":"10","author":"Perrottet","year":"2010","journal-title":"BMC Infect Dis."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1097\/TP.0b013e3182000042","article-title":"Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days","volume":"90","author":"Welker","year":"2010","journal-title":"Transplantation"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00007890-200002150-00014","article-title":"Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients","volume":"69","author":"Fishman","year":"2000","journal-title":"Transplantation"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1001\/jama.1987.03390220080025","article-title":"Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts","volume":"257","author":"Erice","year":"1987","journal-title":"JAMA"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials: table 1","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1128\/JCM.41.2.576-580.2003","article-title":"Diagnosing herpesvirus infections by real-time amplification and rapid culture","volume":"41","author":"van Doornum","year":"2003","journal-title":"J Clin Microbiol."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1128\/AAC.23.5.676","article-title":"Anti-herpesvirus activity of the acyclic nucleoside 9-(1, 3-dihydroxy-2-propoxymethyl) guanine","volume":"23","author":"Smee","year":"1983","journal-title":"Antimicrob Agents Chemother."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1128\/AAC.24.4.518","article-title":"Effect of 9-(1, 3-dihydroxy-2-propoxymethyl) guanine on human cytomegalovirus replication in vitro","volume":"24","author":"Mar","year":"1983","journal-title":"Antimicrob Agents Chemother."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/cid\/ciaa537","article-title":"Valganciclovir dosing for cytomegalovirus prophylaxis in solid-organ transplant recipients on continuous veno-venous hemodialysis","volume":"73","author":"Jarrell","year":"2021","journal-title":"Clin Infect Dis."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:12:08Z","timestamp":1748956328000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001054","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"2022-08-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}